A new study has shed light on how cancer patients' attitudes and beliefs drive the use of complementary and alternative medicine. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the ...
May 26, 2015
0
38
Toni Kay Mangskau has worked at the Mayo Clinic for the past 28 years. Her current position of clinical trials referral coordinator for the Mayo Clinic Cancer Center was created in 2005 after a need was identified for providing ...
May 21, 2015
0
15
In a first-of-its-kind clinical trial, physician-scientists at University Hospitals (UH) Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine found that a new non-invasive technology ...
May 18, 2015
0
20
Mainz-based researchers have made significant advances with regard to the development of individualized immunotherapy strategies for treating cancer. They have managed to identify the relevant genetic changes or mutations ...
May 12, 2015
0
10
Cancer is more likely to develop in people who are very overweight (obese), because surplus body fat interferes with various hormone cycles and with glucose and fat metabolism. On the occasion of European Obesity Day this ...
May 12, 2015
0
20
IBM on Tuesday said 14 US cancer treatment centers would join a partnership to get personalized care treatment plans from the company's Watson supercomputer.
May 5, 2015
0
28
The New England Journal of Medicine reports results of a multi-center phase I/II study of the investigational anti-cancer agent rociletinib (CO-1686) in patients with EGFR-mutant non-small cell lung cancer (NSCLC) that had ...
Apr 29, 2015
0
7
Much of what we know about cancer and many modern medicines that treat it grow from experiments on cancer cells. However, it is notoriously difficult to maintain the integrity of cell lines - due to contamination or simple ...
Apr 22, 2015
0
12
Researchers at the NFCR Center for Cancer System Informatics at MD Anderson Cancer Center have discovered a key factor that may explain drug resistance in glioblastoma (GBM), the most common and deadliest form of brain cancer.
Apr 20, 2015
0
138
More than 60 percent of patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was not responding to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called ...
Apr 20, 2015
0
21
